Skip to main content

Advertisement

SpringerLink
Log in

Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer, and novel therapies are urgently needed to prolong patient survival and improve clinical outcomes. Very few scientific reviews have examined the literature on combination therapies with the goal of describing the available preclinical and clinical data and suggesting future clinical combination treatment schedules. The present review focuses on preclinical and clinical studies of drug combination therapies in ATC. The relevant literature from PubMed and Scopus was reviewed in this article; the ClinicalTrials.gov database was searched for clinical trials not yet published. Recent data from preclinical models strongly support the idea that combination treatments that utilize drugs from different antineoplastic classes have synergistic antitumour activity in ATC. However, rapid translation of these therapies into the clinic is impeded by the difficulty in recruiting enough patients for randomized clinical trials. Although promising results have been obtained in preclinical studies, additional clinical research is required to elucidate the efficacy of combination treatments for clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361(9356):501–11.

    Article  Google Scholar 

  2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–64.

    Article  Google Scholar 

  3. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol. 2005;131(9):585–90. https://doi.org/10.1007/s00432-005-0673-0.

    Article  CAS  PubMed  Google Scholar 

  4. Chintakuntlawar AV, Foote RL, Kasperbauer JL, Bible KC. Diagnosis and management of anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):269–84. https://doi.org/10.1016/j.ecl.2018.10.010.

    Article  PubMed  Google Scholar 

  5. Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983–2002. Am J Clin Oncol. 2008;31(5):460–4. https://doi.org/10.1097/COC.0b013e31816a61f3.

    Article  CAS  PubMed  Google Scholar 

  6. Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–60. https://doi.org/10.1038/nrendo.2017.76.

    Article  CAS  PubMed  Google Scholar 

  7. American Thyroid Association. ATA Guidelines. 2018. https://www.thyroid.org/professionals/ata-professional-guidelines/. Accessed 14 June 2019.

  8. Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17(1):018–0903.

    Article  Google Scholar 

  9. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848–53. https://doi.org/10.1038/sj.bjc.6600361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–39. https://doi.org/10.1089/thy.2012.0302.

    Article  PubMed  Google Scholar 

  11. Pasqualetti G, Ricci S, Boni G, Tognini S, Polini A, Mariani G, et al. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(2):171–6.

    Article  CAS  Google Scholar 

  12. Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib—a case report. Anticancer Res. 2012;32(5):1743–6.

    CAS  PubMed  Google Scholar 

  13. Denaro N, Nigro CL, Russi EG, Merlano MC. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther. 2013;9:1231–41. https://doi.org/10.2147/ott.s46545.

    Article  PubMed  Google Scholar 

  14. Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014;6(6):267–79. https://doi.org/10.1177/1758834014548188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47–55. https://doi.org/10.1016/j.ctrv.2015.11.003.

    Article  CAS  PubMed  Google Scholar 

  16. Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6(1):44. https://doi.org/10.1186/s40169-017-0175-0.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. J Control Release. 2016;240:489–503. https://doi.org/10.1016/j.jconrel.2016.06.012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Ali G, et al. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. Cancer Lett. 2017;411:35–433. https://doi.org/10.1016/j.canlet.2017.09.032.

    Article  CAS  PubMed  Google Scholar 

  19. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006;12(2):600–7. https://doi.org/10.1158/1078-0432.ccr-05-1325.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kim S, Yazici YD, Barber SE, Jasser SA, Mandal M, Bekele BN, et al. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck. 2006;28(5):389–99. https://doi.org/10.1002/hed.20369.

    Article  PubMed  Google Scholar 

  21. di Desidero T, Orlandi P, Gentile D, Bocci G. Effects of pazopanib monotherapy vs pazopanib and topotecan combination on anaplastic thyroid cancer cells. Front Oncol. 2019;9:1202. https://doi.org/10.3389/fonc.2019.01202.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Jing C, Gao Z, Wang R, Yang Z, Shi B, Hou P. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017;7(4):903–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Millet R, Domarkas J, Houssin R, Gilleron P, Goossens JF, Chavatte P, et al. Potent and selective farnesyl transferase inhibitors. J Med Chem. 2004;47(27):6812–20. https://doi.org/10.1021/jm030502y.

    Article  CAS  PubMed  Google Scholar 

  24. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res. 2000;60(3):650–6.

    CAS  PubMed  Google Scholar 

  25. Xu G, Pan J, Martin C, Yeung SC. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(4):1769–77. https://doi.org/10.1210/jcem.86.4.7374.

    Article  CAS  PubMed  Google Scholar 

  26. She M, Jim Yeung SC. Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model. Cancer Lett. 2006;238(2):197–201. https://doi.org/10.1016/j.canlet.2005.07.012.

    Article  CAS  PubMed  Google Scholar 

  27. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab. 2007;92(8):2902–9. https://doi.org/10.1210/jc.2007-0027.

    Article  CAS  PubMed  Google Scholar 

  28. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006;25(16):2304–17. https://doi.org/10.1038/sj.onc.1209267.

    Article  CAS  PubMed  Google Scholar 

  29. Chung YS, Cho S, Ryou HJ, Jee HG, Choi JY, Yoon K, et al. Is there a treatment advantage when paclitaxel and lovastatin are combined to dose anaplastic thyroid carcinoma cell lines? Thyroid. 2011;21(7):735–44. https://doi.org/10.1089/thy.2010.0304.

    Article  CAS  PubMed  Google Scholar 

  30. Park CH, Han SE, Nam-Goong IS, Kim YI, Kim ES. Combined effects of baicalein and docetaxel on apoptosis in 8505c anaplastic thyroid cancer cells via downregulation of the ERK and Akt/mTOR pathways. Endocrinol Metab (Seoul). 8505c;33(1):121–32. https://doi.org/10.3803/EnM.2018.33.1.121.

    Article  CAS  Google Scholar 

  31. Garg M, Kanojia D, Mayakonda A, Ganesan TS, Sadhanandhan B, Suresh S, et al. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci Rep. 2017;7(1):9749. https://doi.org/10.1038/s41598-017-10325-x.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wang W, Zhou J, Zhao L, Chen S. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells. Biomed Pharmacother. 2017;88:985–90. https://doi.org/10.1016/j.biopha.2017.01.135.

    Article  CAS  PubMed  Google Scholar 

  33. Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, et al. Sorafenib and quinacrine target anti-apoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer (ATC). Clin Cancer Res. 2016;22(24):6192–203. https://doi.org/10.1158/1078-0432.ccr-15-2792.

    Article  CAS  PubMed  Google Scholar 

  34. Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am J Surg. 2012;204(6):895–900. https://doi.org/10.1016/j.amjsurg.2012.07.027.

    Article  CAS  PubMed  Google Scholar 

  35. Park KC, Kim SM, Jeon JY, Kim BW, Kim HK, Chang HJ, et al. Synergistic activity of N-hydroxy-7-(2-naphthylthio) heptanomide and sorafenib against cancer stem cells. Anaplastic Thyroid Cancer Neoplasia. 2017;19(3):145–53. https://doi.org/10.1016/j.neo.2016.12.005.

    Article  CAS  PubMed  Google Scholar 

  36. Ball DW, Jin N, Xue P, Bhan S, Ahmed SR, Rosen DM, et al. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep. 2015;34(5):2319–24. https://doi.org/10.3892/or.2015.4225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Feng H, Cheng X, Kuang J, Chen L, Yuen S, Shi M, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis. 2018;9(10):1030. https://doi.org/10.1038/s41419-018-1054-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Che HY, Guo HY, Si XW, You QY, Lou WY. Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. Onco Targets Ther. 2014;7:425–32. https://doi.org/10.2147/ott.s57324.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7(13):17194–211. https://doi.org/10.18632/oncotarget.7839.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018;119(10):1223–322. https://doi.org/10.1038/s41416-018-0296-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Vanden Borre P, Gunda V, McFadden DG, Sadow PM, Varmeh S, Bernasconi M, et al. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget. 2014;5(12):3996–4010. https://doi.org/10.18632/oncotarget.2130.

    Article  PubMed  Google Scholar 

  42. Ingeson-Carlsson C, Martinez-Monleon A, Nilsson M. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture. Exp Cell Res. 2015;338(2):127–35. https://doi.org/10.1016/j.yexcr.2015.08.003.

    Article  CAS  PubMed  Google Scholar 

  43. Chin LH, Hsu SP, Zhong WB, Liang YC. Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells. PLoS ONE. 2015;10(3):e0118674. https://doi.org/10.1371/journal.pone.0118674.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lin BR, Chang CC, Chen LR, Wu MH, Wang MY, Kuo IH, et al. Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2. Mol Cancer Res. 2007;5(11):1111–23. https://doi.org/10.1158/1541-7786.mcr-06-0289.

    Article  CAS  PubMed  Google Scholar 

  45. Zhong WB, Tsai YC, Chin LH, Tseng JH, Tang LW, Horng S, et al. A synergistic anti-cancer effect of troglitazone and lovastatin in a human anaplastic thyroid cancer cell line and in a mouse xenograft model. Int J Mol Sci. 2018;19(7):1834. https://doi.org/10.3390/ijms19071834.

    Article  CAS  PubMed Central  Google Scholar 

  46. Wong K, Di Cristofano F, Ranieri M, De Martino D, Di Cristofano A. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer. Endocr Relat Cancer. 2019;26(4):425–36. https://doi.org/10.1530/erc-19-0011.

    Article  CAS  PubMed  Google Scholar 

  47. Allegri L, Baldan F, Mio C, Puppin C, Russo D, Krystof V, et al. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells. Oncol Rep. 2016;35(4):2413–8. https://doi.org/10.3892/or.2016.4614.

    Article  CAS  PubMed  Google Scholar 

  48. De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett. 2018;439:56–655. https://doi.org/10.1016/j.canlet.2018.09.024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Baldan F, Mio C, Allegri L, Puppin C, Russo D, Filetti S, et al. Synergy between HDAC and PARP inhibitors on proliferation of a human anaplastic thyroid cancer-derived cell line. Int J Endocrinol. 2015;2015:978371. https://doi.org/10.1155/2015/978371.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, et al. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab. 2015;100(2):E253–E261261. https://doi.org/10.1210/jc.2014-3101.

    Article  CAS  PubMed  Google Scholar 

  51. Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, et al. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine. 2016;51(2):274–82. https://doi.org/10.1007/s12020-015-0706-7.

    Article  CAS  PubMed  Google Scholar 

  52. Zhang L, Boufraqech M, Lake R, Kebebew E. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer. Oncotarget. 2016;7(13):16517–28.

    PubMed  PubMed Central  Google Scholar 

  53. Catalano MG, Pugliese M, Gallo M, Brignardello E, Milla P, Orlandi F, et al. Valproic acid, a histone deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid cancer: results of a multicenter randomized controlled phase II/III trial. Int J Endocrinol. 2016;2930414(10):27.

    Google Scholar 

  54. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969–78. https://doi.org/10.1093/emboj/20.24.6969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017;123(21):4114–211.

    Article  CAS  Google Scholar 

  56. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. https://doi.org/10.1200/jco.2017.73.6785.

    Article  CAS  PubMed  Google Scholar 

  57. Murakami H, Ono A, Takahashi T, Onozawa Y, Tsushima T, Yamazaki K, et al. Phase I study of Efatutazone, an oral PPARgamma agonist, in patients with metastatic solid tumors. Anticancer Res. 2014;34(9):5133–41.

    CAS  PubMed  Google Scholar 

  58. Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, et al. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013;98(6):2392–400.

    Article  CAS  Google Scholar 

  59. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232–40. https://doi.org/10.1089/thy.2013.0078.

    Article  CAS  PubMed  Google Scholar 

  60. Gramza A, Balasubramaniam S, Fojo AT, Ward J, Wells SA. Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: phase I results. J Clin Oncol. 2013;31:6074. https://doi.org/10.1200/jco.2013.31.15_suppl.6074.

    Article  Google Scholar 

  61. Zhang Q, Xiao X, Li M, Yu M, Ping F, Zheng J, et al. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. PLoS ONE. 2017;12(10):e0184735. https://doi.org/10.1371/journal.pone.0184735.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Nomura M, Otsuka A, Kondo T, Nagai H, Nonomura Y, Kaku Y, et al. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. Cancer Chemother Pharmacol. 2017;80(5):999–1004. https://doi.org/10.1007/s00280-017-3444-0.

    Article  CAS  PubMed  Google Scholar 

  63. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. https://doi.org/10.1056/NEJMoa1709030.

    Article  CAS  PubMed  Google Scholar 

  64. Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018;9(15):12452–70. https://doi.org/10.18632/oncotarget.23746.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. https://doi.org/10.1186/s13045-019-0779-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Salehian B, Liem SY, Mojazi Amiri H, Maghami E. Clinical trials in management of anaplastic thyroid carcinoma; progressions and set backs: a systematic review. Int J Endocrinol Metab. 2019;17(1):e67759. https://doi.org/10.5812/ijem.67759.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Ferrari SM, Fallahi P, La Motta C, Elia G, Ragusa F, Ruffilli I, et al. Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. Expert Rev Precis Med Drug Dev. 2019;4(1):37–49. https://doi.org/10.1080/23808993.2019.1565940.

    Article  Google Scholar 

Download references

Funding

This study was supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC; IG-17672) to GB.

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Scuola Medica – Via Roma 55, 56126, Pisa, Italy

    Daniela Gentile, Paola Orlandi, Marta Banchi & Guido Bocci

Authors
  1. Daniela Gentile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Orlandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marta Banchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guido Bocci
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GB had the idea for the article. DG, PO, MB and GB performed the literature search and data analysis. DG and GB drafted and/or critically revised the work.

Corresponding author

Correspondence to Guido Bocci.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical approval

Human and animal rights: no animal or human was involved in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gentile, D., Orlandi, P., Banchi, M. et al. Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer. Med Oncol 37, 19 (2020). https://doi.org/10.1007/s12032-020-1345-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-020-1345-2

Keywords

Search

Navigation